ADMA Biologics's EPS (Basic) for the
three
months ended in Dec. 2023 was $-0.08.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.13.
During the past 3 years, the average EPS without NRIGrowth Rate was 75.60% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 54.50% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 29.70% per year.
During the past 13 years, ADMA Biologics's highest 3-Year average EPS without NRI Growth Rate was 75.60% per year. The lowest was -519.70% per year. And the median was 12.20% per year.
ADMA Biologics Earnings per Share (Diluted) Historical Data
The historical data trend for ADMA Biologics's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ADMA Biologics's Earnings per Share (Diluted)
For the Biotechnology subindustry, ADMA Biologics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics's PE Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's PE Ratio distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's PE Ratio falls into.
ADMA Biologics Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
ADMA Biologics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
ADMA Biologics (NAS:ADMA) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
ADMA Biologics Earnings per Share (Diluted) Related Terms
Thank you for viewing the detailed overview of ADMA Biologics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
ADMA Biologics (ADMA Biologics) Business Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADMA has been successfully added to your 